scholarly journals The Use of Complementary and Alternative Medicine among Patients with Inflammatory Bowel Disease Is Associated with Reduced Health-Related Quality of Life

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Randi Opheim ◽  
Marte Lie Høivik ◽  
Tomm Bernklev ◽  
Lars-Petter Jelsness-Jørgensen ◽  
Bjørn Moum
Keyword(s):  
Disease Activity ◽  
Self Efficacy ◽  
Positive Impact ◽  
Background Population ◽  
Sf 36 ◽  
Related Quality ◽  
Health Related ◽  
Inflammatory Bowel ◽  
Cam Use

Background and Aims.Complementary and alternative medicine (CAM) use among patients with inflammatory bowel disease (IBD) is common. The aim of this study was to explore associations between CAM use and health-related quality of life (HRQoL) as well as identifying whether sociodemographic factors, disease activity, and personal resources (self-efficacy) influence HRQoL scores in users and nonusers of CAM.Methods.Measures included sociodemographic and disease-related data, the International-CAM Questionnaire, and General Self-Efficacy Scale. A univariate analysis of variance was used to assess the association between CAM use and HRQoL. The associations between clinical, demographic, and personal factors and HRQoL were examined through linear regression analyses.Results.CAM users had statistically significant lower SF-36 scores compared to nonusers and the background population. Nonusers scored significantly lower compared to the background population in two out of the eight SF-36 dimensions. Independent of CAM use, disease activity had a negative impact and self-efficacy had a positive impact on HRQoL.Conclusions.HRQoL in CAM users with IBD was significantly lower compared to nonusers and the background population. Independent of CAM use, disease activity was negatively associated with HRQoL. Self-efficacy had a positive impact on the mental health dimensions in both CAM users and nonusers.

scholarly journals The Impact of Cytokines on the Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus

2019 ◽  
Vol 8 (6) ◽  
pp. 857 ◽  
Author(s):  
Warren David Raymond ◽  
Gro Østli Eilertsen ◽  
Sharanyaa Shanmugakumar ◽  
Johannes Cornelis Nossent
Keyword(s):  
Disease Activity ◽  
Lupus Erythematosus ◽  
Health Related Quality ◽  
Sf 36 ◽  
Cytokine Levels ◽  
Related Quality ◽  
Health Related ◽  
Ifn Γ ◽  
Tgf Β1

Introduction: Systemic lupus erythematosus (SLE) reduces the health-related quality of life (HRQoL), even during periods of disease quiescence. We investigated whether subclinical inflammation as reflected by cytokine levels is linked with reduced HRQoL. Methods: A cross-sectional study of SLE patients (n = 52, mean age 47.3, 86.5% female) who completed a Short Form Health Survey-36 (SF-36) questionnaire. The clinical and demographic data, scores for the disease activity (SLEDAI-2K), organ damage (SDI), and laboratory data were collected simultaneously. The autoantibody and cytokine levels (IFN-γ, IL-1β, IL-4, IL-6, IL-10, IL-12, IL-17, BAFF, TNF-α, TGF-β1, MIP-1α, MIP-1β and MCP-1 (levels in pg/mL) were quantified by sandwich ELISA. The comparisons and associations were assessed non-parametrically, and a multiple regression determined the effect sizes (ES) of the variables on the SF-36 domain and summary scores. Results: The SF-36 summary and domain scores for SLE patients were significantly (20–40%) lower than in a comparable control group, with the exception of the Mental Health scores (p = 0.06). SLE patients had a normal body mass index (BMI) (median, 24.2 kg/m2), a high rate of smoking (69.2%), and usage of social security benefits (90.4%). TGF-β1 (ES 0.06), IL-12 (ES −0.11), IFN-γ (ES 0.07) and MCP-1 (ES 0.06) influenced the SF-36 domain scores; and MCP-1 (ES 0.04) influenced the Mental Health Summary Score (MCS). Obvious manifestations, including patient visual analogue scale (VAS) (ES −2.84 to −6.29), alopecia (ES −14.89), malar rash (ES −14.26), and analgesic requirement (ES −19.38), independently influenced the SF-36 items; however, the SF-36 scores were not reflected by the physician VAS or disease activity (SLEDAI-2K). Conclusions: Cytokines had a minimal impact on HRQoL in SLE patients, especially compared to visible skin manifestations, central nervous system (CNS) damage, and pain. Better tools are needed to capture HRQoL in measures of disease activity.

scholarly journals P567 Impact of oral ferric maltol and IV iron on health-related quality of life in patients with iron deficiency anaemia and inflammatory bowel disease, and relationship with haemoglobin and serum iron

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S478-S479 ◽  
Author(s):  
S Howaldt ◽  
I Jacob ◽  
M Sampson ◽  
F Akriche
Keyword(s):  
Serum Iron ◽  
Iron Deficiency Anaemia ◽  
Health Related Quality ◽  
Deficiency Anaemia ◽  
Sf 36 ◽  
Related Quality ◽  
Health Related ◽  
Iv Iron ◽  
Inflammatory Bowel

Abstract Background Iron deficiency anaemia (IDA) is common in inflammatory bowel disease (IBD) and can significantly impair health-related quality of life (HRQoL). IV iron is currently the main treatment for patients intolerant or unsuitable for standard oral iron. Ferric maltol (FM), a stable oral complex of ferric iron and maltol, is designed to provide efficient iron delivery and minimise formation of free iron in the gut, thus reducing the potential for gastric adverse events. The HRQoL benefits of FM and ferric carboxymaltose (FCM) and their relationship to haematological parameters were analysed using data from a randomised controlled trial. Methods Patients with IBD and IDA were randomised to FM (30 mg b.i.d) or IV FCM (as per local SmPC) in an open-label, Phase 3b non-inferiority study (primary endpoint haemoglobin [Hb] responder rate [proportion of patients with ≥2 g/dl increase or normalisation of Hb at week 12]; non-inferiority margin 20%). HRQoL was assessed via the Short Form Health Survey (SF-36). In a post-hoc analysis of patient-level data, Hb, serum iron and HRQoL at baseline and week 12 were summarised descriptively and correlations between HRQoL and haematological parameters were assessed via Pearson’s correlation coefficient (PCC). Results 250 patients were randomised: 125 to FM (per-protocol [PP] n = 86) and 125 to IV FCM (PP n = 92). FM was non-inferior to FCM on the primary endpoint (response rate 74% and 83% for FM and IV FCM respectively [PP population], risk difference -0.1 [two-sided p = 0.017; 95% CI -0.2, 0.0]). Hb, serum iron and HRQoL all improved following both treatments at Week 12. Improvements in SF-36 physical component summary (PCS) and mental component summary (MCS) scores were slightly greater with FM (difference not statistically significant; Table 1). HRQoL improved across all SF-36 domain scores with both FM and FCM, with no statistically significant differences between treatments (Figure 1). HRQoL (MCS and PCS) improvements were positively associated with increases in Hb and serum iron (Table 1). Conclusion FM provides non-inferior efficacy to IV FCM with at least as great a benefit to HRQoL and may, therefore, provide an oral alternative to IV iron in patients with IBD.

Sign in / Sign up

Export Citation Format

Share Document